alanine has been researched along with Nervous System Diseases in 11 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Nervous System Diseases: Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although remdesivir (GS-5734) has recently demonstrated clinical benefits against the pandemic outbreak of coronavirus disease 2019 (COVID-19), neuropsychological adverse reactions (ADRs) remain to be examined in real-world settings." | 1.62 | Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports. ( Dragioti, E; Jacob, L; Jung, SY; Kang, HC; Kim, JH; Kim, MS; Kostev, K; Koyanagi, A; Lascu, A; Lee, S; Lee, SW; Salem, JE; Shin, JI; Smith, L; Tizaoui, K; Yang, JW; Yon, DK, 2021) |
| "Primary erythermalgia is a rare disorder characterized by recurrent attacks of red, warm and painful hands, and/or feet." | 1.33 | SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels. ( Drenth, JP; Guillet, G; Jansen, JB; Kirby, RL; Taieb, A; te Morsche, RH, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, S | 1 |
| Yang, JW | 1 |
| Jung, SY | 1 |
| Kim, MS | 1 |
| Yon, DK | 1 |
| Lee, SW | 1 |
| Kang, HC | 1 |
| Dragioti, E | 1 |
| Tizaoui, K | 1 |
| Jacob, L | 1 |
| Koyanagi, A | 1 |
| Salem, JE | 1 |
| Kostev, K | 1 |
| Lascu, A | 1 |
| Shin, JI | 1 |
| Kim, JH | 1 |
| Smith, L | 1 |
| Lee, CJ | 1 |
| Qiu, TA | 1 |
| Sweedler, JV | 1 |
| Wasan, H | 1 |
| Singh, D | 1 |
| Kh, R | 1 |
| McAninch, EA | 1 |
| Jo, S | 1 |
| Preite, NZ | 1 |
| Farkas, E | 1 |
| Mohácsik, P | 1 |
| Fekete, C | 1 |
| Egri, P | 1 |
| Gereben, B | 1 |
| Li, Y | 1 |
| Deng, Y | 1 |
| Patti, ME | 1 |
| Zevenbergen, C | 1 |
| Peeters, RP | 1 |
| Mash, DC | 1 |
| Bianco, AC | 1 |
| Miki, T | 1 |
| Zwingman, TA | 1 |
| Wakamori, M | 1 |
| Lutz, CM | 1 |
| Cook, SA | 1 |
| Hosford, DA | 1 |
| Herrup, K | 1 |
| Fletcher, CF | 1 |
| Mori, Y | 1 |
| Frankel, WN | 1 |
| Letts, VA | 1 |
| Yamamoto-Watanabe, Y | 1 |
| Watanabe, M | 1 |
| Jackson, M | 1 |
| Akimoto, H | 1 |
| Sugimoto, K | 1 |
| Yasujima, M | 1 |
| Wakasaya, Y | 1 |
| Matsubara, E | 1 |
| Kawarabayashi, T | 1 |
| Harigaya, Y | 1 |
| Lyndon, AR | 1 |
| Shoji, M | 1 |
| DEKABAN, A | 1 |
| FIELD, JB | 1 |
| STEVENS, H | 1 |
| Drenth, JP | 1 |
| te Morsche, RH | 1 |
| Guillet, G | 1 |
| Taieb, A | 1 |
| Kirby, RL | 1 |
| Jansen, JB | 1 |
| Jones, LA | 1 |
| Skare, JC | 1 |
| Cohen, AS | 1 |
| Harding, JA | 1 |
| Milunsky, A | 1 |
| Skinner, M | 1 |
| Koeppen, AH | 1 |
| Wallace, MR | 1 |
| Benson, MD | 1 |
| Altland, K | 1 |
| Dunn, HG | 1 |
| Perry, TL | 1 |
| Dolman, CL | 1 |
2 reviews available for alanine and Nervous System Diseases
| Article | Year |
|---|---|
d-Alanine: Distribution, origin, physiological relevance, and implications in disease.
Topics: Alanine; Animals; Diabetes Mellitus; Humans; Kidney Diseases; Liver Cirrhosis; Mental Disorders; Neo | 2020 |
Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies.
Topics: Alanine; Animals; Anticonvulsants; Antiparkinson Agents; Benzylamines; Humans; Monoamine Oxidase; Ne | 2021 |
9 other studies available for alanine and Nervous System Diseases
| Article | Year |
|---|---|
Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports.
Topics: Adenosine Monophosphate; Adverse Drug Reaction Reporting Systems; Alanine; Bayes Theorem; Cohort Stu | 2021 |
Prevalent polymorphism in thyroid hormone-activating enzyme leaves a genetic fingerprint that underlies associated clinical syndromes.
Topics: Adult; Alanine; Amino Acid Substitution; Case-Control Studies; Cerebral Cortex; Gene Frequency; HEK2 | 2015 |
Two novel alleles of tottering with distinct Ca(v)2.1 calcium channel neuropathologies.
Topics: Alanine; Animals; Animals, Newborn; Calbindins; Calcium Channels, N-Type; Cells, Cultured; Cysteine; | 2008 |
Quantification of cystatin C in cerebrospinal fluid from various neurological disorders and correlation with G73A polymorphism in CST3.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Biomarkers; Case | 2010 |
Familial idiopathic hypoglycemia: neurological complications.
Topics: Alanine; Galactose; Glucagon; Glucose Tolerance Test; Humans; Hypoglycemia; Leucine; Nervous System | 1962 |
SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels.
Topics: Adult; Alanine; Conserved Sequence; Cysteine; Erythromelalgia; Female; Genes, Dominant; Heterozygote | 2005 |
Familial amyloidotic polyneuropathy: a new transthyretin position 30 mutation (alanine for valine) in a family of German descent.
Topics: Adult; Alanine; Amyloid; Amyloidosis; Base Sequence; DNA; Female; Germany; Humans; Male; Molecular S | 1992 |
Familial amyloid polyneuropathy: alanine-for-threonine substitution in the transthyretin (prealbumin) molecule.
Topics: Adult; Aged; Alanine; Amyloidosis; Blotting, Southern; DNA; Female; Humans; Isoelectric Focusing; Ma | 1990 |
A syndrome resembling Friedreich's ataxia with relapsing polyneuropathy and hyperalaninemia.
Topics: Alanine; Brain; Child; Child, Preschool; Chronic Disease; Demyelinating Diseases; Diagnosis, Differe | 1968 |